NASDAQ:AKCA Akcea Therapeutics (AKCA) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free AKCA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$18.17▼$18.1750-Day Range$18.13▼$18.1752-Week Range$8.00▼$21.70VolumeN/AAverage Volume361,806 shsMarket Capitalization$1.85 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Akcea Therapeutics alerts: Email Address Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Akcea Therapeutics Stock (NASDAQ:AKCA)Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Read More Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. AKCA Stock News HeadlinesJanuary 6, 2024 | morningstar.comArcturus Therapeutics Holdings Inc ARCTSeptember 27, 2023 | investing.comAKCA Historical DataApril 29, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.January 5, 2022 | investing.comAkcea Therapeutics Inc (AKCA)October 26, 2021 | finance.yahoo.comAkcea Therapeutics to Present at Upcoming Investor ConferencesSee More Headlines Receive AKCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akcea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/04/2020Today4/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AKCA CUSIPN/A CIK1662524 Webwww.akceatx.com Phone617-207-0202FaxN/AEmployees248Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.48 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$40.77 million Net Margins-12.34% Pretax MarginN/A Return on Equity-8.94% Return on Assets-8.02% Debt Debt-to-Equity RatioN/A Current Ratio12.17 Quick Ratio11.78 Sales & Book Value Annual Sales$488.54 million Price / Sales3.78 Cash Flow$0.51 per share Price / Cash Flow35.54 Book Value$5.78 per share Price / Book3.14Miscellaneous Outstanding Shares101,599,000Free FloatN/AMarket Cap$1.85 billion OptionableOptionable Beta1.45 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Paula Soteropoulos (Age 51)CEO & Director Mr. Michael F. MacLean (Age 53)Chief Financial Officer Dr. Louis St. Laurence O'Dea FRCPC (Age 68)MB, BCh, BAO, FRCP(C), Chief Medical Officer Ms. Sarah Boyce (Age 47)Pres & Director Mr. Jeffrey M. Goldberg (Age 46)Chief Operating Officer Key CompetitorsSchrödingerNASDAQ:SDGRAgios PharmaceuticalsNASDAQ:AGIOSyndax PharmaceuticalsNASDAQ:SNDXGeronNASDAQ:GERNNewAmsterdam PharmaNASDAQ:NAMSView All Competitors AKCA Stock Analysis - Frequently Asked Questions How were Akcea Therapeutics' earnings last quarter? Akcea Therapeutics, Inc. (NASDAQ:AKCA) announced its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.14. The firm earned $22.38 million during the quarter, compared to analyst estimates of $30.93 million. Akcea Therapeutics had a negative net margin of 12.34% and a negative trailing twelve-month return on equity of 8.94%. Akcea Therapeutics's quarterly revenue was down 15.9% on a year-over-year basis. During the same period last year, the firm earned ($0.40) EPS. What other stocks do shareholders of Akcea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Advanced Micro Devices (AMD), Apollo Global Management (APO) and Exelixis (EXEL). When did Akcea Therapeutics IPO? Akcea Therapeutics (AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager. This page (NASDAQ:AKCA) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI stock to buy right nowStockEarningsGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akcea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.